Alliance Pharma plc reported preliminary earning results for the year ended December 31, 2017. For the period, the company expects group revenue for 2017 is expected to be £103.3 million representing a 6% increase, with profit before tax expected to be in line with the Board's expectations. There was a significant increase in underlying free cash flow in 2017 to £21.5 million, up from £13.0 million in 2016, underscoring Alliance's ability to generate high levels of cash flow. The improvement on the prior year was due to the continued strong cash generation of the business and the leveling of working capital following the build-up in the first half of 2016 due to the acquisition of the Healthcare Products Business from Sinclair Pharma plc. The Group's net debt was approximately £72.3 million as at 31 December 2017. Consequently adjusted net debt/EBITDA leverage has fallen from 2.8 times to less than 2.5 times at the end of 2017. Based on current business performance, it expects to leverage to continue to reduce to below 2.0 times by the end of 2018.